O'Brien Stephen Paul 4
4 · Tvardi Therapeutics, Inc. · Filed Feb 2, 2026
Research Summary
AI-generated summary of this filing
Tvardi (TVRD) PAO Stephen O'Brien Receives 15,000-Share Award
What Happened
- Stephen Paul O'Brien, Principal Accounting Officer of Tvardi Therapeutics (TVRD), was granted a derivative award of 15,000 shares on January 29, 2026. The reported acquisition price is $0.00 per share (derivative security), indicating a compensation award rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-01-29
- Grant: 15,000 shares (derivative) at $0.00 per share
- Filing date: 2026-02-02 (filed within two business days of the transaction)
- Shares owned after transaction: not specified in the Form 4 summary provided
- Footnote: Shares vest in equal monthly installments over 48 months beginning January 29, 2026, subject to continuous service
Context
- This is a compensation grant (award of derivative securities) that vests over time to incentivize retention; it is not an immediate purchase or sale and does not produce cash proceeds or indicate a market sale.
Insider Transaction Report
Form 4
O'Brien Stephen Paul
Principal Accounting Officer
Transactions
- Award
Employee Stock Option (right to buy)
[F1]2026-01-29+15,000→ 15,000 totalExercise: $3.90Exp: 2036-01-29→ Common Stock (15,000 underlying)
Footnotes (1)
- [F1]The shares subject to the option shall vest and become exercisable in equal monthly installments over 48 months commencing on January 29, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.
Signature
/s/ Dan Conn, Attorney-in-Fact|2026-02-02